Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 0.86 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.86 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.86 |
| ▸ | DRD3 | P35462 | 3/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | TSPO | P30536 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040981 | 1.00 | ADORA3 (0.86) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL1423980 | 1.00 | ADORA3 (0.86) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL29524237 | 1.00 | ADORA3 (0.86) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL1423784 | 0.99 | ADORA3 (0.86) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL1423842 | 0.97 | ADORA3 (0.83) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL31326351 | 0.97 | ADORA3 (0.83) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL29462324 | 0.93 | ADORA3 (1.00) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL22191354 | 0.89 | ADORA3 (0.70) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL1423696 | 0.87 | ADORA3 (0.85) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 | |
| SCHEMBL1424257 | 0.86 | ADORA3 (0.84) | ADORA3TMEM97SIGMAR1DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | claimed |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2022-03-17 | — | — | US | claimed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | claimed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2021-03-11 | — | — | US | claimed |
| CN-111447953-A | A3 adenosine receptor ligands for the management of cytokine release syndrome | 康菲生物制药有限公司 | 2020-07-24 | — | — | CN | claimed |
| EP-3681538-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2020-07-22 | — | — | EP | claimed |
| WO-2020141535-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2020-07-09 | — | — | WO | claimed |
| EP-3530273-A2 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | Can-Fite Biopharma Ltd. (IL) | 2019-08-28 | — | — | EP | claimed |
| WO-2019053723-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2019-03-21 | — | — | WO | claimed |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | CAN-FITE BIOPHARMA LTD. (IL) | 2015-08-06 | — | — | US | claimed |
| EP-2892533-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | Can-Fite Biopharma Ltd. (IL) | 2015-07-15 | — | — | EP | claimed |
| WO-2014024195-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | CAN-FITE BIOPHARMA LTD. (IL) | 2014-02-13 | — | — | WO | claimed |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2013-08-01 | — | — | US | claimed |
| US-8420664-B2 | A3 adenosine receptor allosteric modulators | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-04-16 | — | — | US | claimed |
| US-20120270829-A1 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN | SAINT LOUIS UNIVERSITY (US) | 2012-10-25 | — | — | US | claimed |
| EP-1983990-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | US GOV HEALTH & HUMAN SERV (US) | 2011-03-23 | — | — | EP | claimed |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | THE GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2009-02-26 | — | — | US | claimed |
| EP-1983990-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007089507-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2007-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | ADORA2A, ADORA3, FABP4 | ADORA3 2/4885TMEM97 1674/4885SIGMAR1 994/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885TMEM97 1034/4885SIGMAR1 758/4885 |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | ADORA3, ADORA2A, IL1RN | ADORA3 1/4885TMEM97 2490/4885SIGMAR1 1443/4885 |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885TMEM97 518/4885SIGMAR1 237/4885 |
| US-20130197025-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885TMEM97 801/4885SIGMAR1 192/4885 |
| US-20090054476-A1 | A3 Adenosine receptor allosteric modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885TMEM97 621/4885SIGMAR1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.